The FDA reached a deal to use Entelos' simulation technology to test the effects of three medicines being developed for cardiovascular ailments. Entelos said its Cardiovascular PhysioLab mathematically interprets chemical properties of drugs to predict whether they will cause heart problems and to identify at-risk individuals. The project aims "to anticipate bad scenarios before they occur," an FDA official said.

Related Summaries